Cybin

Cybin IRL is a Canadian pharmaceutical company that is developing psychedelic drugs as medicines.

The company's drug candidates include psilocybin (CYB001), CYB002 (discontinued), CYB003 (deuterated psilocin), CYB004 (deuterated dimethyltryptamine (DMT)), CYB005 (deuterated phenethylamine derivative), and CYB006. Another drug that the company has developed is CYB210010 (2C-T-TFM).

As of January 2025, CYB003 is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 (psilocybin) to have reached this late stage of clinical development.

In 2020, Cybin acquired psychedelic pharmaceutical company Adelia Therapeutics.